 |
|
|
|
|
|
|
|
 |
|
||||||
 |
 |
 |
 |
 |
 |
 |
|
Analyst Conference Summaries
Passage Bio
PASG
conference date: March 3, 2026 press release only
| 2026 | |||
| Passage Bio Q4 2025 press release |
|||
| Mar. 3, 2026 | |||
| 2025 | |||
| Passage Bio Q4 2024 press release |
Passage Bio Q1 2025 press release |
Passage Bio Q2 2025 press release |
Passage Bio Q3 2025 press release |
| Mar. 4, 2025 | May 13, 2025 | Aug. 12, 2025 | Nov. 10, 2025 |
| 2024 | |||
| Passage Bio Q4 2023 press release |
Passage Bio Q1 2024 press release |
Passage Bio Q2 2024 press release |
Passage Bio Q3 2024 press release |
| Mar. 4, 2024 | May 14, 2024 | Aug. 8, 2024 | Nov. 13, 2024 |
| 2023 | |||
| na | na | na | Passage Bio Q3 2023 press release |
| na | na | na | Nov. 13, 2023 |
Passage Bio (PASG) is a clinical-stage biotechnology company specializing in therapies for the central nervous system.
More Analyst Conference Pages:
| AGEN |
| AGIO |
| ALLO |
| ALNY |
| AMAT |
| AMGN |
| APRE |
| ARWR |
| BIIB |
| BMY |
| BOLD |
| CCCC |
| CLDX |
| CBIO |
| FATE |
| GILD |
| ILMN |
| INCY |
| INKT |
| INO |
| IONS |
| IOVA |
| LGND |
| MCHP |
| MRNA |
| PASG |
| REGN |
| RXRX |
| SANA |
| SUPN |
| VRTX |
| VSTM |
| XNCR |
Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.
Copyright 2026 William P. Meyers